Cancer Kills Millions of Dogs. Will Immunotherapy Prolong Their Lives? [The New York Times]
ImmunityBio, Inc. (IBRX)
Company Research
Source: The New York Times
Immunotherapy has transformed cancer treatment. It tinkers with the immune system to attack malignancies that have evaded the body’s natural defenses. This advance offers an alternative to treating cancer with surgery or chemotherapy and radiation, which can attack healthy tissue and cause extreme side effects.The treatment is not only scientifically complex but also expensive. The investment of money and time makes sense when it comes to saving humans. But what about when it comes to dogs?Dr. Hans Klingemann has worked on and researched cancer immunotherapy for decades, leading departments at Rush University Medical Center in Chicago and Tufts Medical Center in Boston. Now, he’s the chief science officer for cellular products at ImmunityBio, which develops immunotherapy drugs for people. But he has also written two papers exploring whether the new treatments might someday prolong canine lives.The interview below has been condensed and edited for clarity.What interests you about immun
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why [Yahoo! Finance]Yahoo! Finance
- ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors [Yahoo! Finance]Yahoo! Finance
- ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint InhibitorsBusiness Wire
- ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update [Yahoo! Finance]Yahoo! Finance
- ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company UpdateBusiness Wire
IBRX
Earnings
- 5/9/24 - Miss
IBRX
Sec Filings
- 6/20/24 - Form S-8
- 6/13/24 - Form 4
- 6/13/24 - Form 4
- IBRX's page on the SEC website